Articles by Cassandra Blohowiak, contributing editor

The Fate of Mannkind

May 1, 2009
By: Cassandra Blohowiak, contributing editor

Al Mann has sunk almost $1 billion of his own money into a new insulin delivery system. Will FDA be persuaded?

Massachusetts Passes New Sales and Marketing Rules

Mar 18, 2009
By: Cassandra Blohowiak, contributing editor

The latest state-level attempt to regulate pharma marketing is also the most stringent, requiring both drug and device manufacturers to track and disclose marketing spend. And the state's very important biotech industry is crying foul.

Genentech and Roche May Be Close to Deal

Mar 3, 2009
By: Cassandra Blohowiak, contributing editor

All signs point to Genentech acquisition.

Astellas to Nominate Two Directors to CV Therapeutics Board

Mar 3, 2009
By: Cassandra Blohowiak, contributing editor

Astellas's hostile bid takes a new turn as the Japanese company tries to oust remaining CVT board members and replace them with their own.

Lilly Gets Green Light to Sell Prasugrel in Europe

Feb 25, 2009
By: Cassandra Blohowiak, contributing editor

Lilly's blood thinner earns approval in Europe and challenges Plavix's status as king of the ACS market.

EMEA/Canada Health Suspend Raptiva Sales

Feb 25, 2009
By: Cassandra Blohowiak, contributing editor

After more reports surface that link Raptiva to a deadly brain infection, world drug regulation agencies decide the risks outweigh benefits.

Pharma Beats Sunshine Act to the Punch

Feb 11, 2009
By: Cassandra Blohowiak, contributing editor

Pfizer is the latest addition to Big Pharma's data disclosure club; the drug giant will be disclosing all physician payments that total more that $500 a year.

GSK and KV Downsize in the Wake of Q4 Numbers

Feb 11, 2009
By: Cassandra Blohowiak, contributing editor

GlaxoSmithKline to lay off thousands while embattled KV Pharma drops 40 percent of its work force in latest wave of cuts.

Astellas Takes Another Stab at CV

Jan 28, 2009
By: Cassandra Blohowiak, contributing editor

Astellas bumped its bid for CV Therapeutics to $1 billion, but analysts doubt the offer is high enough to get the biotech's board of directors to sign on the dotted line.